Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID‐19 patients: A prospective observational study conducted on Pakistani population

Journal of Medical Virology - Tập 93 Số 12 - Trang 6732-6736 - 2021
Qiadat Hasnain Qureshi1, Taimoor Ashraf1, Kanwal Rehman2, Muhammad Kaleem Khosa3, Muhammad Sajid Hamid Akash4
1Department of Medicine, Nishtar Medical University, Multan, Pakistan
2Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
3Department of Chemistry, Government College University Faisalabad, Faisalabad, Pakistan
4Department of Pharmaceutical Chemistry, Government College University Faisalabad, Faisalabad, Pakistan

Tóm tắt

AbstractWe aimed to investigate the interventions of remdesivir in both diabetic and nondiabetic individuals who were suffering from a severe infection of novel coronavirus disease (COVID‐19). In this study, we aimed to explore the relationship between therapeutic effectiveness of remdesivir and complications of diabetes mellitus by observing the recovery period among diabetic and nondiabetic patients associated with COVID‐19 infection. A total of 850 COVID‐19 patients were recruited for this study, out of which 48% were diabetic and 52% were nondiabetics. The results of this study indicated that nondiabetic individuals administered with remdesivir recovered from COVID‐19 within 10 days showing a 95% confidence interval (p < 0.01), while the diabetic individuals recovered in 15 days. Nondiabetic patients administered with remdesivir exhibited higher chances of clinical improvement at 15th day than those who were associated with diabetes. Remdesivir administration improved the levels of various biochemical parameters, such as C‐reactive protein, lactate dehydrogenase, d‐Dimer, and ferritin both in diabetic and nondiabetic patients. However, a significant improvement (p < 0.01) was seen in the level of biochemical parameters among nondiabetic patients as compared to that of diabetic patients administered with remdesivir treatment. In the end, it was concluded that remdesivir could be considered as a possible therapeutic agent in the treatment of COVID‐19 both in diabetic and nondiabetic situations. However, diabetic patients showed a delayed recovery as compared with that of nondiabetic patients, in which the recovery rate was high.

Từ khóa


Tài liệu tham khảo

10.1128/mBio.00221-18

10.1038/s41598-017-04031-x

10.1126/scitranslmed.aal3653

FDA U, 2020, Coronavirus (COVID‐19) update: FDA issues emergency use authorization for potential COVID‐19 treatment, Press Announc, 3

10.1056/NEJMoa2007016

10.1056/NEJMoa2007764

10.1056/NEJMoa2015301

10.1016/j.phrs.2020.104899

10.35787/jimdc.v9i4.532

10.1016/S0140-6736(20)31189-2

US Food Drug Administration. Coronavirus (COVID‐19) update: FDA Issues Emergency Use Authorization for Potential COVID‐19 Treatment FDA News Release. May 1 2020.

10.1001/jama.2017.8334

MundialAM. Declaración de Helsinki de la AMM‐Principios éticos para las investigaciones médicas en seres humanos.2019.

Thông tin
Thông tin xuất bản

Journal of Medical Virology

Tập 93 Số 12

6732-6736

Thông tin tác giả